Proactive Pharmacovigilance and Risk Management

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice, Sixth Edition

Volumn , Issue , 2012, Pages 389-409

  Raine, June ^a   Wise, Lesley ^a   Talbot, John ^b   Aronson, Jeffrey K ^c  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adverse drug reactions; Drug withdrawals; Pharmacovigilance; Pharmacovigilance plan; Proactive risk management; Risk minimization plan; Safety specification

Indexed keywords

EID: 84860696532     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470975053.ch7     Document Type: Chapter

References (37)

1. Honig P, Phillips J, Woodcock J. How many deaths are due to medical error? JAMA 2000; 284(17): 2187-8.
2. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284(23): 3036-9.
3. Woosley RL. Drug labeling revisions-guaranteed to fail? JAMA 2000; 284(23): 3047-9.
4. Waller PC, Evans SJW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12(1): 17-29.
5. ICH E2E Guideline. Pharmacovigilance planning. Geneva: International Conferences on Harmonization, 18 November 2004. http://www.ich.org/cache/compo/475-272-1.html#E2E.
6. Cluxton RJ Jr, Li Z, Heaton PC, Weiss SR, Zuckerman IH, Moomaw CJ, Hsu VD, Rodriguez EM. Impact of regulatory labelling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: finding from the state of Ohio Medicaid program. Pharmacoepidemiol Drug Saf 2005; 14(1): 1-9.
7. European Medicines Agency. Post-authorisation Evaluation of Medicines for Human Use. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine. Revision 1.1, 24 September 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf.
8. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Risk Management Systems for Medicinal Products for Human Use. EMEA/CHMP/96268/2005. London, 14 November 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004888.pdf.
9. European Commission. Volume 9A of the Rules Governing Medicinal Products in the European Union-Guidelines on Pharmacovigilance for Medicinal Products for Human Use. September 2008: 36-55. http://ec.europa.eu/health/files/pharmacos/docs/doc2005/12-05/draft_of_volume_9a_12_2005_en.pdf.
10. Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf 2006; 29(8): 657-73.
11. European Medicines Agency. Post-authorisation Evaluation of Medicines for Human Use. Annex C: template for EU risk management plan (EU-RMP). EMEA/192632/2006. London, 27 September 2006.
12. Alphs LD, Anand R. Clozapine: the commitment to patient safety. J Clin Psychiatry 1999; 60 Suppl 12: 39-42.
13. Honein MA, Lindstrom JA, Kweder SL. Can we ensure the safe use of known human teratogens? The iPLEDGE test case. Drug Saf 2007; 30(1): 5-15.
14. Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharm Stat 2008; 7(1): 20-35.
15. Cooper AJP, Lettis S, Chapman CL, Evans SJW, Waller PC, Shakir S, Payvandi N, Murray AB. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008; 17(5): 445-54.
16. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2005; 363(10): 905-17.
17. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Egbets TCG, Blackburn S, Persson I, Leufkens HG. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 2009; 32(12): 1175-87.
18. Zeldis JB, Williams BA, Thomas SD, Elsayed ME, STEPS: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21(2): 319-30.
19. Chaudhuri A, Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ 2006; 332(7538): 416-9.
20. Department of Health & Human Services. Tysabri Risk Minimization Action Plan: summary of TOUCH. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf.
21. Siegrist C-A, Lewis EM, Eskola J, Evans SJW, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26(11): 979-84.
22. Tanne JH. Four deaths and 350 adverse events lead to US recall of heparin. BMJ 2008; 336(7641): 412-3.
23. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. September 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf.
24. US Department of Health and Human Services, Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.
25. Belen OA. Qualaquin (quinine sulphate) capsules risk evaluation and mitigation strategies (REMS) http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM217721.pdf.
26. Wright C, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability. Ann NY Acad Sci 2008; 1141: 284-303.
27. McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE. Case histories in pharmaceutical risk management. Drug Alcohol Depend 2009; 105 Suppl 1: S42-55.
28. Henningfield JE, Schuster CR. Risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend 2009; 105 Suppl 1: S56-64.
29. Goozner M. Oncologists want FDA to rethink REMS. J Natl Cancer Inst 2010; 102(23): 1748-55.
30. US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Medication Guides-Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS), February 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM244570.pdf.
31. Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. Drug Saf 2009; 32(2): 91-8.
32. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162-7.
33. Pearce SH. Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) 2004; 61(5): 589-94.
34. Lembo A, Weber HC, Farraye FA. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. Drugs 2003; 63(18): 1895-905.
35. Boada JN, Boada C, García-Sáiz M, García M, Fernández E, Gómez E. Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance. PLoS One 2008; 3(10): e3580.
36. Lovibond K, Hutchings A, O'Leary M. An exploration of incremental net health benefit analysis: a quantitative assessment of the benefit-harm profile of natalizumab in relapsing remitting multiple sclerosis. iHEA 2007 6th World Congress: Explorations in Health Economics. http://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=830212.
37. Frau S, Pous MF, Luppino MR, Conforti A. Risk management plans: are they a tool for improving drug safety? Eur J Clin Pharmacol 2010; 66: 785-90.